| Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 20 (5), 497-530, 2022 | 932 | 2022 |
| NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 19 (3), 254-266, 2021 | 880 | 2021 |
| Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma SP Patel, M Othus, Y Chen, GP Wright Jr, KJ Yost, JR Hyngstrom, ... New England Journal of Medicine 388 (9), 813-823, 2023 | 355 | 2023 |
| Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade CRG Stroud, A Hegde, C Cherry, A Rafeh Naqash, N Sharma, ... Journal of Oncology Pharmacy Practice, 2017 | 288 | 2017 |
| Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, A Achufusi, P Armand, ... Journal of the National Comprehensive Cancer Network 20 (4), 387-405, 2022 | 247 | 2022 |
| NCCN guidelines® Insights: non–small cell lung cancer, version 2.2023: featured updates to the NCCN guidelines DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 21 (4), 340-350, 2023 | 229 | 2023 |
| The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases JA Kanakry, AM Hegde, CM Durand, AB Massie, AE Greer, RF Ambinder, ... Blood, The Journal of the American Society of Hematology 127 (16), 2007-2017, 2016 | 201 | 2016 |
| COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials A Desai, JF Gainor, A Hegde, AM Schram, G Curigliano, S Pal, SV Liu, ... Nature reviews Clinical oncology 18 (5), 313-319, 2021 | 157 | 2021 |
| Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies A Hegde, AY Andreev-Drakhlin, J Roszik, L Huang, S Liu, K Hess, ... ESMO open 5 (5), e000799, 2020 | 54 | 2020 |
| A phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies A Hegde, P Jayaprakash, CA Couillault, S Piha-Paul, D Karp, J Rodon, ... Clinical Cancer Research 27 (11), 3050-3060, 2021 | 52 | 2021 |
| Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 … AR Naqash, CRG Stroud, MU Butt, GK Dy, A Hegde, M Muzaffar, LV Yang, ... Acta Oncologica 57 (6), 867-872, 2018 | 37 | 2018 |
| Frailty- The Missing Piece of the Pre- Hematopoietic Cell Transplantation Assessment? A Hegde, H Murthy Bone Marrow Transplantation, 2017 | 31 | 2017 |
| ARC-7: Randomized phase 2 study of domvanalimab+ zimberelimab±etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC). ML Johnson, W Fox, YG Lee, KH Lee, HK Ahn, YC Kim, KY Lee, JS Lee, ... Journal of Clinical Oncology 40 (36_suppl), 397600-397600, 2022 | 29 | 2022 |
| Change in reporting of USMLE Step 1 scores and potential implications for international medical graduates A Desai, A Hegde, D Das JAMA 323 (20), 2015-2016, 2020 | 29 | 2020 |
| Antibiotic use and overall survival in lung cancer patients receiving nivolumab. TP Do, AM Hegde, CR Cherry, CRG Stroud, N Sharma, SD Cherukuri, ... Journal of Clinical Oncology 36 (15_suppl), e15109-e15109, 2018 | 23 | 2018 |
| First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer. D Morgensztern, NE Ready, ML Johnson, A Dowlati, NJ Choudhury, ... Journal of Clinical Oncology 41 (16_suppl), 3002-3002, 2023 | 13 | 2023 |
| Survival is worse in patients completing immunotherapy prior to SBRT/SRS compared to those receiving it concurrently or after S Woody, A Hegde, H Arastu, MS Peach, N Sharma, P Walker, AW Ju Frontiers in Oncology 12, 785350, 2022 | 13 | 2022 |
| Activity of brigatinib in crizotinib and ceritinib-resistant ROS1-rearranged non–small-cell lung cancer A Hegde, DS Hong, A Behrang, SM Ali, L Juckett, F Meric-Bernstam, ... JCO precision oncology 3, 2019 | 12 | 2019 |
| Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma V Subbiah, S Kuravi, S Ganguly, DR Welch, CJ Vivian, MU Mushtaq, ... ESMO open 6 (4), 100172, 2021 | 11 | 2021 |
| Responsiveness to immune checkpoint inhibitors in RET dependent cancers A Hegde, L Huang, S Liu, K Hess, M Cabanillas, M Hu, N Busaidy, ... Cancer Research 79 (13_Supplement), 4997-4997, 2019 | 9 | 2019 |
Mark BowlingEast Carolina University在 ecu.edu 的电子邮件经过验证
